+20%

est. 2Y upside i

HealthcareIPO

Rank

#3263

Sector

Biotechnology, Precision Oncology

Est. Liquidity

~0Y

Data Quality

Data: High

Guardant Health presents a risky equity opportunity with a moderate expected upside over a two-year horizon.

Last updated: March 10, 2026

Bull (25%)+75%

Guardant Health's Shield blood test for multi-cancer early detection gains significant market traction, exceeding 2026 screening revenue guidance of $162M-$174M and demonstrating a clear path to profitability by 2027. This, combined with sustained 30%+ oncology revenue growth, propels the valuation to over $21B, reflecting a premium for market leadership in a rapidly expanding TAM.

Base (45%)+30%

Guardant Health maintains its strong position in precision oncology with continued 25-30% revenue growth, driven by Guardant360 and Reveal. The Shield test shows steady but slower adoption, and the company continues to manage cash burn towards break-even. The valuation reaches approximately $15.8B, aligning with analyst consensus for moderate growth and market share retention.

Bear (30%)-40%

Intensified competition from Natera and Exact Sciences, coupled with slower-than-expected adoption of the Shield test and persistent unprofitability, leads to investor skepticism. The high P/S multiple compresses significantly, and the company faces increased pressure on margins, resulting in a valuation decline to approximately $7.3B.

Est. time to liquidity~0.0 years

Preference Stack Risk

low

Funding Intensity

5%

Investors hold $557M in liquidation preferences, which represents a low 4.56% of the current $12.2B valuation.

Dilution Risk

moderate

As a public company, future stock offerings or option grants could lead to dilution, and a recent shelf filing indicates potential for future capital raises.

Secondary Liquidity

active

As a publicly traded company, employee equity (once vested) is liquid on the open market.

View all 3 open roles at Guardanthealth →

Last updated: February 18, 2026

Questions to Ask at the Interview

Strategic questions based on Guardanthealth's data — designed to show you've done your homework.

  • 1

    “Given the high P/S ratio compared to industry peers and the ongoing net losses, how does Guardant Health plan to demonstrate a clear path to sustainable profitability and justify its current valuation to investors over the next 2-3 years?”

  • 2

    “With strong competitors like Natera and Exact Sciences in the market, what specific strategies is Guardant Health implementing to defend and expand its market share in both therapy selection/MRD monitoring and the emerging multi-cancer early detection space?”

  • 3

    “Considering the company is already public and has recently completed a post-IPO funding round, how does Guardant Health envision managing potential future dilution for employees holding equity, and what are the key milestones for long-term shareholder value creation?”

Community

Valuation Sentiment

Our model estimates +20% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.